P Khoury1, R Desmond2,3, A Pabon1, N Holland-Thomas4, J M Ware1, D C Arthur5, R Kurlander6, M P Fay7, I Maric6, A D Klion1. 1. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 2. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 3. Department of Hematology, Tallaght Hospital, Dublin, Ireland. 4. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702, MD, USA. 5. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 7. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES). METHODS: Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT00044304: registered at clinicaltrials.gov). The primary outcome was an eosinophil count <1.5 × 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. A retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily ≥ 1 month) were classified according to the criteria used in the prospective study. RESULTS: Overall, imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of ≥ 4 myeloid features was the sole predictor of response. After ≥ 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remain in remission off therapy for a median of 29 months (range 14-36). CONCLUSIONS: Clinical features of MHES predict imatinib response in PDGFRA-negative HES. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES). METHODS: Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT00044304: registered at clinicaltrials.gov). The primary outcome was an eosinophil count <1.5 × 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. A retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily ≥ 1 month) were classified according to the criteria used in the prospective study. RESULTS: Overall, imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of ≥ 4 myeloid features was the sole predictor of response. After ≥ 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remain in remission off therapy for a median of 29 months (range 14-36). CONCLUSIONS: Clinical features of MHES predict imatinib response in PDGFRA-negative HES. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Amy D Klion; Pierre Noel; Cem Akin; Melissa A Law; D Gary Gilliland; Jan Cools; Dean D Metcalfe; Thomas B Nutman Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes Journal: Leukemia Date: 2010-09-02 Impact factor: 11.528
Authors: Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich Journal: J Allergy Clin Immunol Date: 2012-03-28 Impact factor: 10.793
Authors: Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter Journal: Br J Haematol Date: 2008-10-17 Impact factor: 6.998
Authors: Animesh Pardanani; Stephanie R Brockman; Sarah F Paternoster; Heather C Flynn; Rhett P Ketterling; Terra L Lasho; Ching-Liang Ho; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi Journal: Blood Date: 2004-07-29 Impact factor: 22.113
Authors: Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Fanny Legrand; Aline Renneville; Elizabeth MacIntyre; Samuel Mastrilli; Felix Ackermann; Jean Michel Cayuela; Philippe Rousselot; Aline Schmidt-Tanguy; Olivier Fain; Marc Michel; Jean-Pierre de Jaureguiberry; Pierre-Yves Hatron; Pascale Cony-Makhoul; Didier Lefranc; Damien Sène; Vincent Cottin; Mohamed Hamidou; Olivier Lidove; André Baruchel; Sylvain Dubucquoi; Olivier Bletry; Claude Preudhomme; Monique Capron; Lionel Prin; Jean Emmanuel Kahn Journal: Medicine (Baltimore) Date: 2013-09 Impact factor: 1.889
Authors: Sandhya R Panch; Michael E Bozik; Thomas Brown; Michelle Makiya; Calman Prussin; Donald G Archibald; Gregory T Hebrank; Mary Sullivan; Xiaoping Sun; Lauren Wetzler; JeanAnne Ware; Michael P Fay; Cynthia E Dunbar; Steven I Dworetzky; Paneez Khoury; Irina Maric; Amy D Klion Journal: Blood Date: 2018-05-08 Impact factor: 22.113
Authors: Dara Burris; Chen E Rosenberg; Justin T Schwartz; Yin Zhang; Michael D Eby; J Pablo Abonia; Patricia C Fulkerson Journal: J Allergy Clin Immunol Pract Date: 2019-05-22